- 全部删除
 
您的购物车当前为空
Avizakimab (BOS161721,艾维奇单抗) 是一种人源化lgG1单克隆抗体,靶向IL-21并且抑制其生物活性,具有治疗系统性红斑狼疮(SLE)的潜力。

为众多的药物研发团队赋能,
让新药发现更简单!
Avizakimab (BOS161721,艾维奇单抗) 是一种人源化lgG1单克隆抗体,靶向IL-21并且抑制其生物活性,具有治疗系统性红斑狼疮(SLE)的潜力。
| 规格 | 价格 | 库存 | 数量 | 
|---|---|---|---|
| 1 mg | ¥ 2,320  | In stock | |
| 5 mg | ¥ 5,490  | In stock | |
| 10 mg | ¥ 7,480  | In stock | |
| 25 mg | ¥ 10,900  | In stock | |
| 50 mg | ¥ 14,800  | In stock | |
| 100 mg | ¥ 19,800  | In stock | 
Avizakimab 相关产品
| 产品描述 | Avizakimab (BOS161721) is a humanized lgG1 monoclonal antibody that targets and inhibits the biological activity of IL-21, with potential for the treatment of systemic lupus erythematosus (SLE).  | 
| 体外活性 | Avizakimab 可结合 IL-22 并阻断其与 IL-22R1 的结合,从而抑制下游 STAT3 磷酸化[1]。  | 
| 别名 | 艾维奇单抗, BOS161721, BOS 161721 | 
| CAS No. | 2229685-51-0 | 
| 颜色 | Transparent | 
| 物理性状 | Liquid | 
| 存储 | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | 
评论内容